Alzheimer’s Association International Conference | July 28 – Aug. 1, 2024 | Philadelphia, USA, and Online

AAIC Abstract and Session Submission Guidelines

AAIC offers unparalleled exposure for your research across the field. Submit your abstract or session proposal for the opportunity to feature your work among thousands of abstracts submitted on the latest dementia research. Highlight your work in front of dementia researchers from around the globe and bring key opinion leaders together to impact the future of the field. Opportunities to present in person and online will be available.

Read Full Submission Guidelines

On This Page:

Submit an Abstract to AAIC

Individual abstract submissions provide an opportunity for presenting authors to share and discuss designs, data and analyses with AAIC attendees. The following abstract types are eligible for submission to AAIC:

  • Original: The abstract primarily contains new designs, data or analyses that will not be published or presented prior to AAIC 2024.
  • Update: The abstract provides updates on designs, data or analyses that have been published or presented prior to AAIC 2024.
  • Encore: The abstract will be published verbatim prior to AAIC 2024. Please note, encore abstracts will not be published in Alzheimer’s & Dementia.

“Published” refers to publication in a journal as a full article or conference abstract, or publication on a preprint server, while “Presented” refers to presentation at a regional, national or international conference. If your abstract is currently under review, please select the category your abstract meets at the time of submission then email to change category upon publication.

Individual abstracts can be submitted for consideration for an oral and/or a poster presentation, with original, update, and encore abstracts all eligible for oral or poster presentations. Abstracts first undergo peer review that considers the quality of and interest in the abstract. Then, informed by the peer review scores, the Scientific Program Committee (SPC) selects certain abstracts for oral presentations.

The presenting author of an abstract may attend either in-person or virtually for either oral or poster presentations.

Submit a Session Proposal to AAIC

It is also possible to organize and submit a session proposal and help shape the program at AAIC 2024.

Featured Research Sessions (FRS) debut and discuss innovative and impactful research findings, drawing together multiple studies that share a common focus.

  • FRS are 90 minutes in length, and comprise 2 chairs and 4-6 presenters, with each presenter submitting an structured abstract. Original, update and encore abstracts are all eligible for inclusion.
  • The chairs of featured research sessions are akin to journal editors for a special issue, who invite presenting authors to share their latest study findings.
  • If an FRS is not accepted, abstracts that receive an appropriate average score are automatically considered by the Scientific Program Committee for an oral or poster presentation. There is no need to submit an abstract twice.

Perspectives Sessions provide both an expert review of recent advances and propose a road-map for the future, incorporating multiple viewpoints to stimulate original discussion and debate. Perspectives Sessions should interest and engage the core audience of the field being discussed, and also offer an entryway for attendees from other fields. Perspectives Sessions can be invited by the Scientific Program Committee or submitted as an entire session.

  • Perspectives Sessions are 90 minutes in length, and comprise 2 chairs and 4-6 presenters, with each presenter submitting an unstructured abstract that may or may not contain new findings, data or analyses.
  • The chairs of perspectives sessions are akin to senior authors of a review paper, who invite presenting authors to prepare individual sections of the review.
  • If a Perspectives Session is not accepted, abstracts are automatically considered by the SPC for an oral or poster presentation. There is no need to submit an abstract twice.

For both Featured Research and Perspectives Sessions, each chair and presenter may attend either in-person or virtually, with any combination of in-person and virtual attendance permitted. Unless the topic demands otherwise, the session should be diverse in terms of the demographics of presenters.

Submit an Abstract to a Preconference

Abstracts submitted to AAIC can also be submitted to the Alzheimer’s Imaging Consortium (AIC) or the Technology and Dementia preconferences as part of the submission process. Please note, the AIC and the Technology and Dementia preconferences take place in-person only and require an additional registration fee to AAIC.

Please submit the abstract to AAIC, and select the appropriate answer to the question "Should this abstract also be submitted to a pre-conference?" during the submission process. The abstract will be considered for both AAIC and the selected preconference.

Themes, Topics and Subtopics

Selection of a theme, topic and subtopic for the abstract allows submitters to "self-identify" the area in which the abstract best fits. This identification is the first step in sorting abstracts for the Scientific Program Committee, who will take this identification into consideration and group related abstracts with similar topics into the same session. Selection of a primary theme, topic and subtopic is required.

New for AAIC 2024: Submit a case study to share your findings with the dementia research and care community. Case studies present findings on a single individual and provide scientific considerations based on the case for the audience. They may describe a rare or unique clinical presentation, novel empirically-based course of treatment or treatment response, or instance when the outcome of a case did or did not fit with the current research literature.

Accepted themes:

Theme: Basic Science and Pathogenesis

  • Topic: Genetics
    • Blood-borne markers of CNS disease
    • Endophenotypes
    • Epigenetics
    • Genetic factors of Alzheimer’s disease
    • Genetic factors of non-Alzheimer’s disease
    • Genetics of cognitive aging
    • Genetics of systems biology
  • Topic: Human Neuropathology

    Your work must include data derived from postmortem human tissue, alone or in combination with other datasets, to meet criteria for human neuropathology.

    • AI and digital pathology
    • Alpha-synuclein
    • Amyloid
    • Clinico-pathologic correlations
    • Etiopathogenesis—links to brain disease
    • Imaging-pathologic correlations
    • Novel methods
    • Proteinopathies
    • Selective vulnerability
    • Tau
    • Topography of pathology
    • Vascular
    • And others
  • Topic: Molecular and Cell Biology
    • α-synuclein
    • APP/Abeta/Amyloid
    • Cell cycle disruption
    • Endosomal-lysosomal dysfunction
    • Innate immunity
    • Lipids
    • Metabolic stress
    • Mitochondrial function/energetics
    • Neurodegeneration and neuroprotection
    • Neuroinflammation
    • Oxidative stress
    • Presenilins
    • Prion-like
    • Protein-protein interactions
    • Proteostasis
    • Receptors
    • Signal transduction
    • Stem cells; IPS cells
    • Synaptic disruption
    • Systemic/adaptive immunity
    • Tau
    • TDP-43
    • Therapeutic strategy
    • Vascular factors
    • And others

Theme: Biomarkers

  • Topic: Biomarkers (non-neuroimaging)
    • Differential diagnosis
    • Digital biomarkers
    • Human neuropathology
    • Longitudinal change over time
    • Method development and/or quality control
    • Multi-modal comparisons
    • Novel biomarkers
    • Plasma/serum/urine biomarkers
    • Prognostic utility
    • Use in clinical trial design and evaluation
  • Topic: Neuroimaging
    • Animal imaging
    • Differential diagnosis
    • Evaluating treatments
    • Imaging and genetics
    • Multi-modal comparisons
    • New imaging methods
    • Normal brain aging
    • Optimal neuroimaging measures for early detection
    • Optimal neuroimaging measures for tracking disease progression

Theme: Clinical Manifestations

  • Topic: Neuropsychiatry and Behavioral Neurology
    • Assessment/measurement/epidemiology of neuropsychiatric/behavioral and psychological symptoms
    • Clinical aspects of behavioral neurology and neuropsychiatry
    • Dementia
    • Interventions
    • Mild cognitive impairment/early symptomatic prodromal disease
    • Normal cognition/subjective cognitive decline/preclinical disease
    • Treatment development and clinical trials for neuropsychiatric symptoms
  • Topic: Neuropsychology
    • Computerized neuropsychological assessment
    • Early detection of cognitive decline with neuropsychological tests
    • Measurements of function
    • Multicultural issues in assessment of dementia
    • Neuropsychological correlates of physiologic markers of cognitive decline/dementia
    • Neuropsychological profiles of dementia
    • Normal cognitive aging

Theme: Dementia Care Research and Psychosocial Factors

  • Topic: Dementia Care Research (research projects; nonpharmacological)
    • Assessment and care planning
    • Behavioral interventions
    • Community care
    • Cross-cultural studies and cultural/linguistic adaptations
    • Family/lay caregiving
    • Instrument development, program evaluation and translation
    • Long-term care
    • Therapeutic strategies and interventions
    • Use of technologies
  • Topic: Psychosocial Factors and Environmental Design
    • Environmental design and technology
    • Living with dementia and quality of life
    • Social networks

Theme: Dementia Care Practice

  • Topic: Dementia Care Practice (descriptive)
    • Implementation of person-centered care
    • Managing dementia-related behaviors
    • Supportive and therapeutic environments
    • Transition and coordination of services
    • Workforce initiatives
    • Other innovative programs and practices

Theme: Drug Development

  • Topic: Human
    • Human trials: Anti-amyloid
    • Human trials: Anti-tau
    • Human trials: Cognitive enhancement
    • Human trials: Inflammation
    • Human trials: Nutraceuticals and non-pharmacological interventions
    • Human trials: Other
    • Human trials: Other behavioral symptoms
    • Novel outcomes measures
    • Prevention (clinical)
    • Trial design
  • Topic: Nonhuman
    • Lead optimization studies
    • Natural products and nutraceuticals
    • Nonpharmacological interventions
    • Novel screening strategies
    • Target identification and validation studies: Amyloid
    • Target identification and validation studies: Cognitive enhancement and other behavioral symptoms
    • Target identification and validation studies: Inflammation and innate immunity
    • Target identification and validation studies: Neuronal and synaptic protection
    • Target identification and validation studies: Tau
    • Target identification and validation studies: Other

Theme: Public Health

  • Topic: Epidemiology
    • Health services research
    • Innovative methods in epidemiology (i.e. assessment methods, design, recruitment strategies, statistical methods, etc.)
    • Prevalence, incidence and outcomes of MCI and dementia
    • Risk and protective factors in MCI and dementia
  • Topic: Health Services Research
    • Cost-effectiveness of treatment/prevention and diagnosis
    • Cost of care
    • Policy and plans
    • Services
  • Topic: Prevention (nonpharmacological)
    • Cognitive interventions
    • Exercise
    • Lifestyle factors (e.g., smoking, etc.)
    • Multidomain
    • Nutrition
    • Other

Advance Your Career

Join ISTAART, an inclusive global network of scientists, clinicians and dementia professionals. With newly discounted rates and free memberships for students, it’s easier than ever to become a part of ISTAART.

Learn More

Join the Conversation #AAIC24

We use cookies to improve your experience on this website. Learn about options for managing your personal data in our Privacy Policy.